These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
570 related articles for article (PubMed ID: 23918606)
1. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606 [TBL] [Abstract][Full Text] [Related]
2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
3. It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma. Jahangiri A; Weiss WA Clin Cancer Res; 2013 Nov; 19(21):5811-3. PubMed ID: 24097859 [TBL] [Abstract][Full Text] [Related]
4. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Guenther MK; Graab U; Fulda S Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606 [TBL] [Abstract][Full Text] [Related]
7. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218 [TBL] [Abstract][Full Text] [Related]
8. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236 [TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244 [TBL] [Abstract][Full Text] [Related]
10. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
11. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358 [TBL] [Abstract][Full Text] [Related]
12. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163 [TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
14. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218 [TBL] [Abstract][Full Text] [Related]
15. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349 [TBL] [Abstract][Full Text] [Related]
16. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343 [TBL] [Abstract][Full Text] [Related]
17. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Holt SV; Logie A; Davies BR; Alferez D; Runswick S; Fenton S; Chresta CM; Gu Y; Zhang J; Wu YL; Wilkinson RW; Guichard SM; Smith PD Cancer Res; 2012 Apr; 72(7):1804-13. PubMed ID: 22271687 [TBL] [Abstract][Full Text] [Related]
18. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144 [TBL] [Abstract][Full Text] [Related]
19. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
20. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]